Medical/Pharmaceuticals
Nanoform 1Q 2022 report: Quarterly record of new projects and new customers
HELSINKI, May 24, 2022 /PRNewswire/ -- The positive momentum continues. A quarterly record of eight new non-GMP projects with seven different customers signed. Revenue grew by 174%, the number of employees by 49%, while the total operating costs grew by 27%. The gross margin rose to 92%. Signific...
2022-05-24 14:16
1505
Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma
* First study conducted in the adjuvant setting with a combination of BRAF and MEK inhibitors in high-risk stage II BRAF V600E/K-mutant cutaneous melanoma * A global partnership between EORTC and Pierre Fabre to advance research in melanoma CASTRES, France and BRUSSELS, May 24, 2022 /PRNewswir...
2022-05-24 14:15
1634
RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting
YANTAI, China, May 23, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced that three abstracts for disitamab vedotin (RC48) have been selected for poster discussions by the 2022 American Society of Clinical Oncology (ASCO) Ann...
2022-05-24 10:27
1754
SwipeRx secures US$27 Million in Series B Funding to accelerate growth across Southeast Asia
SINGAPORE, May 24, 2022 /PRNewswire/ -- SwipeRx (formerly mClinica Pharmacy Solutions),Southeast Asia's (SEA) leading platform for pharmacies, announced it has secured a Series B round ofUS$27 million in equity and debt to accelerate growth across SEA. The round was led byIndonesia's MDI Ventures...
2022-05-24 10:00
1984
OptraSCAN's Artificial Intelligence-Equipped Digital Pathology Scanner OS-SiA Granted U.S Patent for Scanning, Indexing and Analyzing of the Tissue Area at the Same Time
SAN JOSE, Calif., May 24, 2022 /PRNewswire/ -- OptraSCAN®
2022-05-24 09:00
2819
SCAI & CBS Pulmonary Hypertension Masterclass 2022: Based on Global Perspectives Focusing on New Breakthroughs
SHANGHAI, May 24, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM innovative platform, recently announced that onMay 12, 2022, the "Pulmonary Hypertension Masterclass 2022" webinar was successfully held, co-organized by the National Center of Pulmonary Vascular Disease,Chi...
2022-05-24 08:30
1994
HistoSonics Announces Agreement with GE Healthcare
HistoSonics Breakthrough Liver Therapy System to Utilize GE's LOGIQ™ E10 for Real-Time Imaging Guidance and Treatment Verification MINNEAPOLIS, May 23, 2022 /PRNewswire/ -- HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agre...
2022-05-23 21:00
2749
New Horizon Health Partners with Prenetics in Hong Kong to Launch ColoClear, a Non-Invasive Stool DNA Test to Detect Colon Cancer
HANGZHOU, China and HONG KONG, May 23, 2022 /PRNewswire/ -- New Horizon Health (6606.HK) and Prenetics Group Limited (Nasdaq: PRE, "Prenetics") has announced a strategic partnership to launch ColoClear by Circle (ColoClear), the "First Colorectal Cancer Screening Test approved inChina", in Hong K...
2022-05-23 20:46
3812
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
SYDNEY, May 23, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at two upcoming investor conferences. Dr Garner will present on behalf of Kazia at the HC ...
2022-05-23 20:30
2821
Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand
The latest geographic growth increases Medison's global footprint across 25
countries in four continents, further strengthening its commercial offering
PETACH TIKVAH, Israel, May 23, 2022 /PRNewswire/ -- Medison Pharma
2022-05-23 20:28
3111
VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone
SHANGHAI, May 23, 2022 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, today announced positive top-line results from its pivotal phase 3 trial, a randomized, open-label, active-controlled trial that compared lonapegsomatropin (TransCo...
2022-05-23 15:57
1266
Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas
SHANGHAI and HONG KONG, May 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...
2022-05-23 10:10
2659
Hanmi Fine Chemical Launches 'high-tech CDMO' Business
CDMO business initiated such as mRNA vaccine raw materials·peptides 10 billion KRW invested in Hanmi Fine Chemical facility expansion SEOUL, South Korea, May 22, 2022 /PRNewswire/ -- Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutical Group specializing in APIs(Active...
2022-05-23 08:32
1966
WHO Goodwill Ambassador for Leprosy Elimination Recognized with WHO Director-General's Award for Global Health at 75th World Health Assembly
Ambassador will call on countries to strengthen efforts against leprosy in meetings with delegations attending WHA TOKYO, May 22, 2022 /PRNewswire/ -- WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa arrives inGeneva, Switzerland on May 23 for the 75th World Health Assembly, where ...
2022-05-23 00:00
2162
Tulip Partners with Stanley Black & Decker on Global Operations Platform
* Platform to provide digital manufacturing solutions for Stanley Black & Decker operations * Jane Arnold, Vice President of Manufacturing Technology at Stanley Black & Decker, to join Tulip's Board of Directors BOSTON, May 21, 2022 /PRNewswire/ -- Tulip Interfaces ("Tulip") announced today t...
2022-05-21 03:53
8281
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini")...
2022-05-21 01:19
9516
Meihua International Medical Technologies Co., Ltd. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 20-F
YANGZHOU, China, May 20, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced that on May 18,...
2022-05-20 22:57
7015
Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias
EPLive 2022 is a two-day conference that draws the world's top cardiac electrophysiology experts AUSTIN, Texas, May 20, 2022 /PRNewswire/ -- On June 2 and 3, 2022, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its sixth international symposium on complex a...
2022-05-20 20:08
3452
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
* Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients * PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in theESR1 mutation population * Data d...
2022-05-20 16:17
3007
Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited
STOCKHOLM, May 20, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment inJune 2022. T...
2022-05-20 14:56
2331
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 281 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 276 media titles]
2024-04-15 08:00
Most Read
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3817
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
2024-04-15 08:00
3083
Goldpac Exhibits at InnoEx 2024
2024-04-13 10:00
3003
